solid pancreatic masses
Conditions
Interventions
In EUS-FNA, 1st puncture using 25-G Franseen needle and 2nd puncture using 22-G Franseen needle.
In EUS-FNA, 1st puncture using 22-G Franseen needle and 2nd puncture using 25-G Franseen needle.
Sponsors
Okayama University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with solid pancreatic masses who are referred to EUS-FNA
Exclusion criteria
Exclusion criteria: 1)Patients with Performance status 4 2)Patients who have risk of bleeding, or with platelet count less than fifty thousand/mm2 3)Patients with anti-thrombotic agent 2 or more 4)Patients with pancreatic mass which we cannot detect by EUS 5)Pregnant woman 6)Patients less than 20 years old 7)Patients who do not agree to participate in this study 8)Patients who determined to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The tissue collection rate in each needle (cellularity score: 3,4,5) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Histological core collection rate in each needle(cellularity score: 5) 2)The tissue collection rate based on the tumor size, location, puncture rout and each pancreatic disease 3)Onsite diagnostic adequacy in each needle 4)Diagnostic accuracy in each needle 5)Specimen bloodiness in each needle 6)Ease of puncture in each needle 7)Needle visibility in each needle 8)Technical success rate in each needle 9)Adverse events | — |
Countries
Japan
Contacts
Public ContactTakeshi Tomoda
Okayama University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed